The drug manufacturer plans to temporarily halt shipments of the Gardasil vaccine to China’e, at least until the middle of the year.
Merck did not make any statements about the pause in its fourth-quarter earnings report, but Gardasil’in sales in the last quarter of last year declined to $1.55 billion (approximately €1.47 billion); The main reason for this was the ongoing low demand trend in China’.
The Gardasil vaccine protects against cancer-causing human papillomavirus or HPV infections. The announcement of the pause came a month after Merck’in received approval in China’ for the use of the vaccine in men.
Merck, headquartered in ’, Rahway, New Jersey, expects adjusted earnings for 2025 to range from $8.88 to $9.03 per share and $64.1 billion to $65.6 billion in sales.
According to FactSet’, analysts had forecast earnings of $9.13 per share on sales of $67.07 billion.
In the recently completed fourth quarter, Merck posted adjusted profits of $1.72 per share on $15.6 billion in revenue. Best selling cancer treatment Keytruda’'s sales %It rose 19 percent to $7.84 billion.
Analysts expected earnings of $1.61 per share and revenues of $15.48 billion.
Merck & Co. Inc. ’ shares in pre-market trading on Tuesday %8 or 8.18 $ Decreased by 91.61 $’a is down.
